Ali Mirzazadeh1, Shelley N Facente2, Katie Burk3, James G Kahn4, Meghan D Morris5. 1. Department of Epidemiology and Biostatistics, University of California, San Francisco; Institute for Global Health Sciences, University of California, San Francisco. Electronic address: Ali.Mirzazadeh@ucsf.edu. 2. Facente Consulting, San Francisco, CA; School of Public Health, University of California, Berkeley. 3. Community Health Equity and Promotion Branch, San Francisco Department of Public Health, San Francisco, CA. 4. Philip R Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco; Institute for Global Health Sciences, University of California, San Francisco; School of Public Health, University of California, Berkeley.
Abstract
PURPOSE: Hepatitis C virus (HCV) is the most common blood-borne infection in the United States, and a leading cause of liver disease, transplant, and mortality. CDC HCV elimination goals include reducing HCV-related mortality by 65% (from 2015) by 2030. METHODS: We used vital registry data (CDC WONDER) to estimate overall and demographic-specific HCV-related mortality from 1999 to 2019 in San Francisco and then used an exponential model to project progress toward HCV elimination. Local trends were compared to state and national trends. RESULTS: Between 1999 and 2019, there were 1819 HCV-related deaths in San Francisco, representing an overall age-adjusted mortality rate of 9.4 (95% CI 9.0, 9.9) per 100,000 population. The age-adjusted HCV-related mortality rates were significantly higher among males (13.7), persons aged 55 years and older (28.0), Black and/or African Americans (32.2) compared to other racial groups, and Hispanic/Latinos (11.6) compared to non-Hispanic and/or Latinos. Overall and in most subgroups, mortality rates were lowest between 2015 and 2019. Since 2015, San Francisco observed a significantly larger reduction in agbe-adjusted HCV-related mortality than California or the U.S. Projected age-adjusted HCV-related mortality rates for San Francisco for 2020 and 2030 were 4.7 (95% CI 3.5, 6.2) and 1.1 (95% CI 0.7, 1.8), respectively. CONCLUSIONS: Based on trends between 2015 and 2019, San Francisco, California, and the U.S. are projected to achieve 65% reduction in HCV-mortality at or before 2030. Based on current trends, San Francisco is projected to achieve this goal earlier.
PURPOSE: Hepatitis C virus (HCV) is the most common blood-borne infection in the United States, and a leading cause of liver disease, transplant, and mortality. CDC HCV elimination goals include reducing HCV-related mortality by 65% (from 2015) by 2030. METHODS: We used vital registry data (CDC WONDER) to estimate overall and demographic-specific HCV-related mortality from 1999 to 2019 in San Francisco and then used an exponential model to project progress toward HCV elimination. Local trends were compared to state and national trends. RESULTS: Between 1999 and 2019, there were 1819 HCV-related deaths in San Francisco, representing an overall age-adjusted mortality rate of 9.4 (95% CI 9.0, 9.9) per 100,000 population. The age-adjusted HCV-related mortality rates were significantly higher among males (13.7), persons aged 55 years and older (28.0), Black and/or African Americans (32.2) compared to other racial groups, and Hispanic/Latinos (11.6) compared to non-Hispanic and/or Latinos. Overall and in most subgroups, mortality rates were lowest between 2015 and 2019. Since 2015, San Francisco observed a significantly larger reduction in agbe-adjusted HCV-related mortality than California or the U.S. Projected age-adjusted HCV-related mortality rates for San Francisco for 2020 and 2030 were 4.7 (95% CI 3.5, 6.2) and 1.1 (95% CI 0.7, 1.8), respectively. CONCLUSIONS: Based on trends between 2015 and 2019, San Francisco, California, and the U.S. are projected to achieve 65% reduction in HCV-mortality at or before 2030. Based on current trends, San Francisco is projected to achieve this goal earlier.
Authors: Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson Journal: Hepatology Date: 2018-11-06 Impact factor: 17.425
Authors: Philip R Spradling; Yuna Zhong; Anne C Moorman; Loralee B Rupp; Mei Lu; Eyasu H Teshale; Mark A Schmidt; Yihe G Daida; Joseph A Boscarino; Stuart C Gordon Journal: Clin Infect Dis Date: 2021-02-09 Impact factor: 9.079
Authors: Reena Mahajan; Jian Xing; Stephen J Liu; Kathleen N Ly; Anne C Moorman; Loralee Rupp; Fujie Xu; Scott D Holmberg Journal: Clin Infect Dis Date: 2014-02-12 Impact factor: 9.079
Authors: Kathleen N Ly; Arialdi M Miniño; Stephen J Liu; Henry Roberts; Elizabeth M Hughes; John W Ward; Ruth B Jiles Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Shelley N Facente; Eduard Grebe; Katie Burk; Meghan D Morris; Edward L Murphy; Ali Mirzazadeh; Aaron A Smith; Melissa A Sanchez; Jennifer L Evans; Amy Nishimura; Henry F Raymond Journal: PLoS One Date: 2018-04-11 Impact factor: 3.240